Verve Therapeutics Stock Soars 75% as Eli Lilly Nears $1.3 Billion Deal for the Gene-Editing Biotech
(Reuters) - Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming to strengthen its pipeline of experimental medicines, the Financial Times reported on Monday.
Shares of Verve Therapeutics soared 75% in after-hours trading.
The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based on the genetic medicines company achieving certain clinical milestones, the report said, citing people familiar with the matter.
The deal could be announced as early as this week, provided talks stay on track, the report added.
Verve Therapeutics is currently developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs.
Eli Lilly declined to comment, while Verve Therapeutics did not immediately respond to a Reuters request for comment outside regular business hours.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10